MRNA Raise PT to $67 from $49 but remain Neutral rated 49 ahead of the first potential Phase 3 mRNA cancer vaccine data @ GSCO

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.